FDA Eases Rules for Certifying Medical Gases
Published Date: 2/12/2026
Notice
Summary
The FDA just dropped a fresh draft guide on how companies should get their medical gases certified and report yearly. This update makes the rules clearer and easier for businesses that make these important gases, saving them time and hassle. If you’re in the medical gas world, check it out and send your thoughts by April 13, 2026!
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Clearer Certification Rules for Medical Gases
The FDA published a draft guidance that explains how companies must request certification for designated medical gases and what annual reports to file. The guidance describes who must submit a certification request, what information to include, and how FDA will evaluate requests; it aligns with regulations that became effective on December 18, 2025.
Defined List of Designated Medical Gases
The guidance and implementing statute identify oxygen, nitrogen, nitrous oxide, carbon dioxide, helium, medical air, and carbon monoxide as designated medical gases (DMGs). If your company manufactures, processes, packs, labels, or distributes any of these gases, those products are within the certification process described in the guidance.
Cover Letter Use and Paperwork Change
FDA recommends using a cover letter with certification requests, amendments, and supplements and plans to revise its information collection to support that practice. FDA estimates the cover letter will take about 1 hour per response and estimates 9 total annual responses, for a total estimated burden of 9 hours annually.
Form Location and Labeling Alignment
The draft guidance removes an attached certification request form and directs users to Form FDA 3864 and instructions at FDA's online forms site; it also revises labeling discussion to align with 21 CFR 201.161. These editorial and form-location changes are intended to match the revised regulations effective December 18, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17215, Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
2026-17229, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
Previous / Next Documents
Previous: 2026-02788, Agency Information Collection Activities: Information Collection Renewal; Comment Request; Reporting, Recordkeeping, and Disclosure Requirements Associated With Proprietary Trading and Certain Interests in and Relationships With Covered Funds
The Office of the Comptroller of the Currency (OCC) is asking for feedback on renewing paperwork rules for banks about their trading and investments in certain funds. This affects banks that do proprietary trading or have ties to covered funds, aiming to keep reporting clear and manageable. Comments are due by April 13, 2026, helping the OCC balance oversight without extra hassle or cost.
Next: 2026-02790, 30-Day Notice of Proposed Information Collection: JADE Act Questionnaire
The Department of State wants to keep using the JADE Act Questionnaire for Burmese visa applicants, asking for public feedback over the next 30 days. About 22,800 people fill out this form yearly, spending around 30 minutes each time. This helps the government check visa eligibility while making sure the process stays clear and fair, with no extra costs or delays expected.